6-Sulfatoxymelatonin as a predictor of clinical outcome in depressive patients


Autoria(s): HIDALGO, Maria Paz Loayza; CAUMO, Wolnei; DANTAS, Giovana; FRANCO, Daiane Gil; TORRES, Iraci Lucena da Silva; PEZZI, Julio; ELISABETSKY, Elaine; DETANICO, Bernardo Carraro; PIATO, Angelo; MARKUS, Regina P.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

20/10/2012

20/10/2012

2011

Resumo

Objectives This study established the value of the 6-sulfatoxymelatonin (aMT6s) urine concentration as a predictor of the therapeutic response to noradrenaline reuptake inhibitors in depressive patients. Methods Twenty-two women aged 18-60 years were selected. Depressive symptoms were assessed by using the Hamilton Depression Scale. Urine samples were collected at 0600-1200 h, 1200-1800 h, 1800-2400 h, and 2400-0600 h intervals, 1 day before and 1 day after starting on the nortriptyline treatment. Urine aMT6s concentration was analyzed by a one-way analysis of variance/Bonferroni test. Spearman`s rank correlation coefficient was used to analyze the correlation between depressive symptoms after 2 weeks of antidepressant treatment and the increase in aMT6s urine concentration. Results Higher and lower size effect groups were compared by independent Student`s t-tests. At baseline, the 2400- to 0600-h interval differed from all other intervals presenting a significantly higher aMT6s urine concentration. A significant difference in aMT6s urine concentrations was found 1 day after treatment in all four intervals. Higher size effect group had lower levels of depressive symptoms 2 weeks after the treatment. A positive correlation between depressive symptoms and the delta of aMT6s in the 2400-0600h interval was observed. Conclusion Our results reinforce the hypothesis that aMT6s excretion is a predictor of clinical outcome in depression, especially in regard to noradrenaline reuptake inhibitors. Copyright (C) 2011 John Wiley & Sons, Ltd.

RPM

RPM

FAPESP

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Pró-Reitoria de Pesquisa da USP (PRP-USP)

Universidade de São Paulo - Pró-Reitoria de Pesquisa PRPq-USP

CNPq

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

MPH

MPH

FIPE-HCPA

FIPE-HCPA

GD

GD

CAPES

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

ILST

ILST

EE

EE

JPC

JPC

Sociedade de Psiquiatria do Rio Grande do Sul

Sociedade de Psiquiatria do Rio Grande do Sul

DGF

Deutsche Forschungsgemeinschaf (DFG)

Identificador

HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, v.26, n.3, p.252-257, 2011

0885-6222

http://producao.usp.br/handle/BDPI/27462

10.1002/hup.1204

http://dx.doi.org/10.1002/hup.1204

Idioma(s)

eng

Publicador

WILEY-BLACKWELL

Relação

Human Psychopharmacology-clinical and Experimental

Direitos

restrictedAccess

Copyright WILEY-BLACKWELL

Palavras-Chave #depression #tricyclic antidepressant #melatonin #6-sulfatoxymelatonin (aMT6s) #SEQUENCED TREATMENT ALTERNATIVES #STAR-ASTERISK-D #MOOD DISORDERS #MELATONIN SECRETION #RATING-SCALE #ANTIDEPRESSANTS #PATHOPHYSIOLOGY #NOREPINEPHRINE #RATIONALE #SEROTONIN #Clinical Neurology #Pharmacology & Pharmacy #Psychiatry #Psychology
Tipo

article

original article

publishedVersion